Interventions for age-related macular degeneration: Are practice guidelines based on systematic reviews?

Ophthalmology

Volumn 123, Issue 4, 2016, Pages 884-897

  Lindsley, Kristina ^a   Li, Tianjing ^a   Ssemanda, Elizabeth ^a   Virgili, Gianni ^b   Dickersin, Kay ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; COCHRANE LIBRARY; DIET SUPPLEMENTATION; EVIDENCE BASED PRACTICE; HUMAN; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELIABILITY; REVIEW; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; DIETARY SUPPLEMENT; EVIDENCE BASED MEDICINE; FACTUAL DATABASE; LASER COAGULATION; LITERATURE; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; REPRODUCIBILITY; STANDARDS;

ANGIOGENESIS INHIBITORS; DATABASES, FACTUAL; DIETARY SUPPLEMENTS; EVIDENCE-BASED MEDICINE; HUMANS; LASER COAGULATION; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PRACTICE GUIDELINES AS TOPIC; REPRODUCIBILITY OF RESULTS; REVIEW LITERATURE AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84956926399     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.12.004     Document Type: Review

References (107)

1. Age-Related Eye Disease Study Research Group Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11 Arch Ophthalmol 121 2003 1621 1624
2. D. Pascolini, and S.P. Mariotti Global estimates of visual impairment: 2010 Br J Ophthalmol 96 2012 614 618
3. Verteporfin in Photodynamic Therapy Study Group Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. One-year results of a randomized clinical trial - VIP report no. 1 Ophthalmology 108 2001 841 852
4. D.R. Lally, A.T. Gerstenblith, and C.D. Regillo Preferred therapies for neovascular age-related macular degeneration Curr Opin Ophthalmol 23 2012 182 188
5. J.P.T. Higgins, and S. Green Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2 [updated March 2011] 2011 The Cochrane Collaboration
6. Institute of Medicine Clinical Practice Guidelines We Can Trust 2011 The National Academies Press Washington, DC
7. A. Lundh, S. Sismondo, J. Lexchin, and et al. Industry sponsorship and research outcome Cochrane Database Syst Rev 12 2012 MR000033
8. E. Lucenteforte, L. Moja, V. Pecoraro, and et al. Discordances originated by multiple meta-analyses on interventions for myocardial infarction: a systematic review J Clin Epidemiol 68 2015 246 256
9. T. Li, S.S. Vedula, R. Scherer, and K. Dickersin What comparative effectiveness research is needed? A framework for using guidelines and systematic reviews to identify evidence gaps and research priorities Ann Intern Med 156 2012 367 377
10. T. Li, A.M. Ervin, R. Scherer, and et al. Setting priorities for comparative effectiveness research: a case study using primary open-angle glaucoma Ophthalmology 117 2010 1937 1945
11. T. Li, K. Dickersin, and R. Scherer Re: registering systematic reviews CMAJ 182 2010 13 14
12. R.B. Haynes, D.L. Sackett, G.H. Guyatt, and P. Tugwell Clinical Epidemiology: How to Do Clinical Practice Research 3rd ed. 2005 Lippincott Williams & Wilkins Philadelphia
13. S. Ip, N. Hadar, S. Keefe, and et al. Web-based archive of systematic review data Syst Rev 1 2012 15
14. Critical Appraisal Skills Programme UK. Critical Appraisal Skills Programme (CASP): making sense of evidence. Available at: http://www.casp-uk.net/#!casp-tools-checklists/c18f8. Accessed March 31, 2015.
15. B.J. Shea, J.M. Grimshaw, G.A. Wells, and et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews BMC Med Res Methodol 7 2007 10
16. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med 6 2009 e1000097
17. T. Yu, T. Li, K.J. Lee, and et al. Setting priorities for comparative effectiveness research on management of primary angle closure: a survey of Asia-Pacific clinicians J Glaucoma 24 2015 348 355
18. American Academy of Ophthalmology Retina/Vitreous Panel Preferred Practice Pattern Guidelines. Age-related macular degeneration 2015 American Academy of Ophthalmology San Francisco, CA Available at: www.aao.org/ppp Accessed February 21, 2015
19. C.M. Eandi, F. Giansanti, and G. Virgili Macular translocation for neovascular age-related macular degeneration Cochrane Database Syst Rev 4 2008 CD006928
20. J.R. Evans Ginkgo biloba extract for age-related macular degeneration Cochrane Database Syst Rev 1 2013 CD001775
21. J.R. Evans, and J.G. Lawrenson Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration Cochrane Database Syst Rev 6 2012 CD000253
22. J.R. Evans, and J.G. Lawrenson Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration Cochrane Database Syst Rev 11 2012 CD000254
23. J.R. Evans, V. Sivagnanavel, and V. Chong Radiotherapy for neovascular age-related macular degeneration Cochrane Database Syst Rev 5 2010 CD004004
24. P. Gehlbach, T. Li, and E. Hatef Statins for age-related macular degeneration Cochrane Database Syst Rev 3 2012 CD006927
25. A. Geltzer, A. Turalba, and S.S. Vedula Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration Cochrane Database Syst Rev 1 2013 CD005022
26. F. Giansanti, C.M. Eandi, and G. Virgili Submacular surgery for choroidal neovascularisation secondary to age-related macular degeneration Cochrane Database Syst Rev 2 2009 CD006931
27. J.G. Lawrenson, and J.R. Evans Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration Cochrane Database Syst Rev 11 2012 CD010015
28. M.B. Parodi, G. Virgili, and J.R. Evans Laser treatment of drusen to prevent progression to advanced age-related macular degeneration Cochrane Database Syst Rev 3 2009 CD006537
29. U. Reddy, and M. Kryzstolik Antiangiogenic therapy with interferon alfa for neovascular age-related macular degeneration Cochrane Database Syst Rev 1 2006 CD005138
30. S.S. Vedula, and M.G. Krzystolik Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration Cochrane Database Syst Rev 2 2008 CD005139
31. G. Virgili, and A. Bini Laser photocoagulation for neovascular age-related macular degeneration Cochrane Database Syst Rev 3 2007 CD004763
32. M.A. Williams, G.J. McKay, and U. Chakravarthy Complement inhibitors for age-related macular degeneration Cochrane Database Syst Rev 1 2014 CD009300
33. R. Wormald, J. Evans, L. Smeeth, and K. Henshaw Photodynamic therapy for neovascular age-related macular degeneration Cochrane Database Syst Rev 3 2007 CD002030
34. J.W. Cheng, S.W. Cheng, G.C. Lu, and R.L. Wei Effect of intravitreal anti-vascular endothelial growth factor therapy on the risk of arterial thromboembolic events: a meta-analysis PLoS One 7 2012 e41325
35. E.W. Chong, T.Y. Wong, A.J. Kreis, and et al. Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis BMJ 335 2007 755
36. J. Evans Antioxidant supplements to prevent or slow down the progression of AMD: a systematic review and meta-analysis Eye 22 2008 751 760
37. W.G. Hodge, D. Barnes, H.M. Schachter, and et al. Evidence for the effect of omega-3 fatty acids on progression of age-related macular degeneration: a systematic review Retina 27 2007 216 221
38. S. Jiang, C. Park, and J.C. Barner Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab J Clin Pharm Ther 39 2014 234 239
39. L. Lee, T.L. Packer, S.H. Tang, and S. Girdler Self-management education programs for age-related macular degeneration: a systematic review Australas J Ageing 27 2008 170 176
40. C. Meads, and C. Hyde Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review Br J Ophthalmol 88 2004 212 217
41. C. Schmucker, C. Ehlken, H.T. Agostini, and et al. A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus gold standard PLoS One 7 2012 e42701
42. C. Schmucker, C. Ehlken, L.L. Hansen, and et al. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review Curr Opin Ophthalmol 21 2010 218 226
43. C. Schmucker, Y.K. Loke, C. Ehlken, and et al. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review Br J Ophthalmol 95 2011 308 317
44. J.S. Schouten, E.C. La Heij, C.A. Webers, and et al. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 247 2009 1 11
45. A.L. Takeda, J. Colquitt, A.J. Clegg, and J. Jones Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review Br J Ophthalmol 91 2007 1177 1182
46. C. Wild, S. Mathis, B. Guba, and G. Gartlehner Rheopheresis for age-related macular degeneration Der Ophthalmologe 106 2009 127 132
47. F. Ziemssen, S. Grisanti, K.U. Bartz-Schmidt, and M.S. Spitzer Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence? Drugs Aging 26 2009 295 320
48. J.Y. Chuo, M. Wiens, M. Etminan, and D.A. Maberley Use of lipid-lowering agents for the prevention of age-related macular degeneration: a meta-analysis of observational studies Ophthalmic Epidemiol 14 2007 367 374
49. A.F. Cruess, G. Zlateva, A.M. Pleil, and B. Wirostko Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties Acta Ophthalmol 87 2009 118 132
50. C.I. Falkner, H. Leitich, F. Frommlet, and et al. The end of submacular surgery for age-related macular degeneration? A meta-analysis Graefes Arch Clin Exp Ophthalmol 245 2007 490 501
51. P. Hooper, J.W. Jutai, G. Strong, and E. Russell-Minda Age-related macular degeneration and low-vision rehabilitation: a systematic review Can J Ophthalmol 43 2008 180 187
52. M.S. Ip, I.U. Scott, G.C. Brown, and et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology Ophthalmology 115 2008 1837 1846
53. P. Lanzetta, P. Mitchell, S. Wolf, and D. Veritti Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review Br J Ophthalmol 97 2013 1497 1507
54. P. Mitchell A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab Curr Med Res Opin 27 2011 1465 1475
55. H.P. Sin, D.T. Liu, and D.S. Lam Lifestyle modification, nutritional and vitamins supplements for age-related macular degeneration Acta Ophthalmol 91 2013 6 11
56. R. Vishwanathan, M. Chung, and E.J. Johnson A systematic review on zinc for the prevention and treatment of age-related macular degeneration Invest Ophthalmol Vis Sci 54 2013 3985 3998
57. F.D. Zhang, L. Wang, and M.Q. Cai Role of lutein in preventing/slowing down age-related macular degeneration: a meta-analysis Chinese J Clin Nutrition 18 2010 126 131
58. J. Zhou, and Q. Lu Meta-analysis of anti-vascular endothelial growth factor combined with photodynamic therapy in treatment of age-related macular degeneration J Shanghai Jiaotong University (Medical Science) 32 2012 1621 1627
59. A. Brown, W. Hodge, A. Cruess, and et al. Management of Neovascular Age-Related Macular Degeneration: Systematic Drug Class Review and Economic Evaluation. Technology Report Number 110 2008 Canadian Agency for Drugs and Technologies in Health Ottawa
60. Haute Autorite de sante/French National Authority for Health Treatment of Age-Related Macular Degeneration [Traitements de la dégénérescence maculaire liée à l'âge] 2001 Agence Nationale d'Accréditation et d'Évaluation en Santé (ANAES) Paris, France
61. G. Oliva, and L. Navarro Age-Related Macular Degeneration: The Role of Current Treatment Strategies 2009 Catalan Agency for Health Technology Assessment and Research (CAHTA) Barcelona
62. J.L. Colquitt, J. Jones, S.C. Tan, and et al. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation Health Technol Assess 12 2008 iii iiv ix-201
63. D.R. Husereau, V. Shukla, B. Skidmore, and D. Maberley Photodynamic therapy with verteporfin for the treatment of neovascular age-related macular degeneration: a clinical assessment 2002 Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 40
64. C. Meads, C. Salas, T. Roberts, and et al. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation Health Technol Assess 7 9 2003 v vi 1-05
65. G. Oliva Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration 2002 Catalan Agency for Health Technology Assessment and Research (CAHTA) Barcelona
66. Macugen AMD Study Group, R.S. Apte, M. Modi, and et al. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration Ophthalmology 114 2007 1702 1712
67. J.S. Heier, A.N. Antoszyk, P.R. Pavan, and et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study Ophthalmology 113 2006 633 642
68. P.J. Rosenfeld, D.M. Brown, J.S. Heier, and et al. Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
69. D.M. Brown, P.K. Kaiser, M. Michels, and et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
70. J.S. Heier, D.S. Boyer, T.A. Ciulla, and et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study Arch Ophthalmol 124 2006 1532 1542
71. R. Lazic, and N. Gabric Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration Ophthalmology 114 2007 1179 1185
72. R. Hahn, S. Sacu, S. Michels, and et al. Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macular degeneration Ophthalmologe 104 2007 588 593
73. Z.F. Bashshur, A. Schakal, R.N. Hamam, and et al. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration Arch Ophthalmol 125 2007 1357 1361
74. C.D. Regillo, D.M. Brown, P. Abraham, and et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1 Am J Ophthalmol 145 2008 239 248
75. G. Weigert, S. Michels, S. Sacu, and et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study Br J Ophthalmol 92 2008 356 360
76. D.S. Boyer, J.S. Heier, D.M. Brown, and et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration Ophthalmology 116 2009 1731 1739
77. C. Costagliola, M.R. Romano, M. Rinaldi, and et al. Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration Br J Ophthalmol 94 2010 180 184
78. M.L. Subramanian, G. Abedi, S. Ness, and et al. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial Eye 24 2010 1708 1715
79. A. Tufail, P.J. Patel, C. Egan, and et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicenter randomised double masked study BMJ 340 2010 c2459
80. CATT Research Group, D.F. Martin, M.G. Maguire, and et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
81. P. Biswas, S. Sengupta, R. Choudhary, and et al. Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration Indian J Ophthalmol 59 2011 191 196
82. U. Schmidt-Erfurth, B. Eldem, R. Guymer, and et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study Ophthalmology 118 2011 831 839
83. P.S. Fleming, J. Seehra, A. Polychronopoulou, and et al. Cochrane and non-Cochrane systematic reviews in leading orthodontic journals: a quality paradigm? Eur J Orthod 35 2013 244 248
84. S.L. MacDonald, S.E. Canfield, S.F. Fesperman, and P. Dahm Assessment of the methodological quality of systematic reviews published in the urological literature from 1998 to 2008 J Urol 184 2010 648 653
85. T. Aziz, S. Compton, U. Nassar, and et al. Methodological quality and descriptive characteristics of prosthodontic-related systematic reviews J Oral Rehabil 40 2013 263 278
86. A. Delaney, S.M. Bagshaw, A. Ferland, and et al. The quality of reports of critical care meta-analyses in the Cochrane Database of Systematic Reviews: an independent appraisal Crit Care Med 35 2007 589 594
87. A.R. Jadad, M. Moher, G.P. Browman, and et al. Systematic reviews and meta-analyses on treatment of asthma: critical evaluation BMJ 320 2000 537 540
88. A. Lundh, S.L. Knijnenburg, A.W. Jørgensen, and et al. Quality of systematic reviews in pediatric oncology - a systematic review Cancer Treat Rev 35 2009 645 652
89. L.P. Moja, E. Telaro, R. D'Amico, and et al. Assessment of methodological quality of primary studies by systematic reviews: results of the metaquality cross sectional study BMJ 330 2005 1053
90. B. Windsor, I. Popovich, V. Jordan, and et al. Methodological quality of systematic reviews in subfertility: a comparison of Cochrane and non-Cochrane systematic reviews in assisted reproductive technologies Hum Reprod 27 2012 3460 3466
91. A.C. Melchiors, C.J. Correr, R. Venson, and R. Pontarolo An analysis of quality of systematic reviews on pharmacist health interventions Int J Clin Pharm 34 2012 32 42
92. V.R. Cornelius, M.J. Perrio, S.A. Shakir, and L.A. Smith Systematic reviews of adverse effects of drug interventions: a survey of their conduct and reporting quality Pharmacoepidemiol Drug Saf 18 2009 1223 1231
93. S. Saokaew, and G.M. Oderda Quality assessment of the methods used in published opioid conversion reviews J Pain Palliat Care Pharmacother 26 2012 341 347
94. H.J. Seo, and K.U. Kim Quality assessment of systematic reviews or meta-analyses of nursing interventions conducted by Korean reviewers BMC Med Res Methodol 12 2012 129
95. C.R. Weir, N. Staggers, and T. Laukert Reviewing the impact of computerized provider order entry on clinical outcomes: the quality of systematic reviews Int J Med Inform 81 2012 219 231
96. T. Li, and G.B. Bartley Publishing systematic reviews in ophthalmology: new guidance for authors Ophthalmology 121 2014 438 439
97. E.A. Vanner, and S.L. Mansberger Putting the "metal" back in meta-analysis Am J Ophthalmol 160 2015 849 850
98. Cochrane Methodological Expectations of Cochrane Intervention Reviews (MECIR) Standards for the reporting of new Cochrane Intervention Reviews. Version 1.1 December 17, 2012 Available at: http://editorial-unit.cochrane.org/mecir Accessed March 31, 2015
99. T. Wu, X. Yang, and X. Zeng Why so many 'RCTSs' were false? A further investigation about ethics review status of the 'RCTs' published in Chinese journals. Poster presentation at the 17th Cochrane Colloquium; 2009 Oct 11-14, Singapore [abstract] Cochrane Database Syst Rev Suppl 2009 51
100. T. Li, and K. Dickersin Citation of previous meta-analyses on the same topic: a clue to perpetuation of incorrect methods? Ophthalmology 120 2013 1113 1119
101. K.C. Siontis, T. Hernandez-Boussard, and J.P. Ioannidis Overlapping meta-analyses on the same topic: survey of published studies BMJ 347 2013 f4501
102. L. Moja, E. Lucenteforte, K.H. Kwag, and et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration Cochrane Database Syst Rev 9 2014 CD011230
103. S.D. Solomon, K. Lindsley, S.S. Vedula, and et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration Cochrane Database Syst Rev 8 2014 CD005139
104. D. Moher The problem of duplicate systematic reviews BMJ 347 2013 f5040
105. M.J. Bolland, and A. Grey A case study of discordant overlapping meta-analyses: vitamin D supplements and fracture PLoS One 9 2014 e115934
106. T. Li, M.A. Puhan, S.S. Vedula, and et al. Network meta-analysis-highly attractive but more methodological research is needed BMC Med 9 2011 79
107. C.D. Mulrow, D.J. Cook, and F. Davidoff Systematic reviews: critical links in the great chain of evidence Ann Intern Med 126 1997 389 391